Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Other Accumulated Expenses (2017 - 2025)

Puma Biotechnology (PBYI) has disclosed Other Accumulated Expenses for 9 consecutive years, with $142000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Accumulated Expenses changed N/A year-over-year to $142000.0, compared with a TTM value of $142000.0 through Dec 2025, changed N/A, and an annual FY2025 reading of $142000.0, changed N/A over the prior year.
  • Other Accumulated Expenses was $142000.0 for Q4 2025 at Puma Biotechnology, down from $171000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $733000.0 in Q2 2021 and bottomed at $81000.0 in Q3 2024.
  • Average Other Accumulated Expenses over 5 years is $361315.8, with a median of $316000.0 recorded in 2024.
  • The sharpest move saw Other Accumulated Expenses surged 138.6% in 2023, then plummeted 69.32% in 2024.
  • Year by year, Other Accumulated Expenses stood at $632000.0 in 2021, then plummeted by 65.98% to $215000.0 in 2022, then soared by 138.6% to $513000.0 in 2023, then plummeted by 84.21% to $81000.0 in 2024, then surged by 75.31% to $142000.0 in 2025.
  • Business Quant data shows Other Accumulated Expenses for PBYI at $142000.0 in Q4 2025, $171000.0 in Q3 2025, and $138000.0 in Q2 2025.